Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $934,644.78 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 14,142 shares of the stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $66.09, for a total transaction of $934,644.78. Following the completion of the transaction, the executive vice president owned 37,302 shares of the company’s stock, valued at $2,465,289.18. This represents a 27.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Eric Swayze also recently made the following trade(s):

• On Thursday, October 2nd, Eric Swayze sold 12,972 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $66.23, for a total transaction of $859,135.56.
• On Tuesday, September 2nd, Eric Swayze sold 11,130 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $49.67, for a total transaction of $552,827.10.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ:IONS opened at $69.15 on Friday. The stock has a market cap of $11.02 billion, a price-to-earnings ratio of -37.58 and a beta of 0.33. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.87 and a quick ratio of 2.86. Ionis Pharmaceuticals, Inc. has a 12 month low of $23.95 and a 12 month high of $69.25. The stock’s 50 day moving average price is $52.25 and its 200 day moving average price is $40.58.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.51. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 28.25%.The firm had revenue of $452.00 million during the quarter, compared to analyst estimates of $270.90 million. During the same period last year, the company posted ($0.45) EPS. The firm’s quarterly revenue was up 100.9% on a year-over-year basis. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Stifel Nicolaus set a $43.00 price target on shares of Ionis Pharmaceuticals in a research report on Thursday, August 21st. Guggenheim lifted their price objective on shares of Ionis Pharmaceuticals from $90.00 to $92.00 and gave the stock a “buy” rating in a research note on Tuesday, September 23rd. JPMorgan Chase & Co. increased their target price on shares of Ionis Pharmaceuticals from $48.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, August 25th. Piper Sandler lifted their price target on shares of Ionis Pharmaceuticals from $62.00 to $65.00 and gave the stock an “overweight” rating in a research report on Friday, August 22nd. Finally, Bank of America increased their price objective on Ionis Pharmaceuticals from $81.00 to $83.00 and gave the company a “buy” rating in a research report on Tuesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $73.88.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in IONS. GAMMA Investing LLC lifted its holdings in shares of Ionis Pharmaceuticals by 3,786.5% in the first quarter. GAMMA Investing LLC now owns 28,993 shares of the company’s stock valued at $961,000 after purchasing an additional 28,247 shares in the last quarter. Fifth Third Bancorp raised its position in Ionis Pharmaceuticals by 4.8% during the first quarter. Fifth Third Bancorp now owns 9,989 shares of the company’s stock valued at $301,000 after buying an additional 458 shares during the period. Exchange Traded Concepts LLC lifted its stake in Ionis Pharmaceuticals by 1,722.5% in the 1st quarter. Exchange Traded Concepts LLC now owns 3,244 shares of the company’s stock worth $98,000 after acquiring an additional 3,066 shares in the last quarter. Moisand Fitzgerald Tamayo LLC acquired a new stake in Ionis Pharmaceuticals during the 1st quarter worth about $151,000. Finally, Sovran Advisors LLC grew its stake in Ionis Pharmaceuticals by 91.4% during the 1st quarter. Sovran Advisors LLC now owns 328,904 shares of the company’s stock valued at $9,341,000 after acquiring an additional 157,092 shares in the last quarter. 93.86% of the stock is currently owned by hedge funds and other institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.